Conditions: Narcolepsy
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 33
Healthy volunteers: no

Brief summary:
This is a study to evaluate the safety and effectiveness of ADX-N05 compared to placebo in the treatment of excessive daytime sleepiness in adults with narcolepsy.

Detailed description:

Arms:
arm 1: Participants first receive a placebo to match ADX-N05 once a day for 2 consecutive weeks (Weeks 1 and 2). They will then receive ADX-N05 150 mg tablet once a day for seven days (Week 3) followed by 300 mg (2 tablets) once a day for seven days (Week 4). arm 2: Participants first receive ADX-N05 150 mg tablet once a day for seven days (Week 1) followed by 300 mg (2 tablets) once a day for seven days (Week 2). They will then receive a placebo to match ADX-N05 once a day for 2 consecutive weeks (Weeks 3 and 4).

Interventions: intervention 1: ADX-N05 intervention 2: Placebo
Intervention descriptions: intervention 1: 150 mg once a day for seven days followed by 300 mg once a day for seven days intervention 2: Placebo to match ADX-N05 once a day for 2 consecutive weeks

Protocol document: